Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.03
(4.17%)
HKD 0.03
(4.17%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 471.29 Million HKD | -8.23% |
| 2022 | 506.22 Million HKD | 4.83% |
| 2021 | 482.88 Million HKD | -13.11% |
| 2020 | 555.74 Million HKD | -25.77% |
| 2019 | 748.7 Million HKD | 32.99% |
| 2018 | 562.99 Million HKD | 67.12% |
| 2017 | 336.87 Million HKD | 257.92% |
| 2016 | 94.11 Million HKD | 288.89% |
| 2015 | 24.2 Million HKD | -65.47% |
| 2014 | 70.08 Million HKD | -0.67% |
| 2013 | 70.55 Million HKD | 19.93% |
| 2012 | 58.83 Million HKD | -47.4% |
| 2011 | 111.84 Million HKD | 115.72% |
| 2010 | 51.84 Million HKD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 273.88 Million HKD | 0.0% |
| 2023 Q1 | 123.63 Million HKD | -47.42% |
| 2023 Q2 | 243.79 Million HKD | 97.18% |
| 2023 FY | 464.54 Million HKD | -8.23% |
| 2023 Q4 | 220.74 Million HKD | 97.08% |
| 2023 Q3 | 112 Million HKD | -54.06% |
| 2022 Q1 | 133.73 Million HKD | -46.95% |
| 2022 FY | 506.22 Million HKD | 4.83% |
| 2022 Q4 | 235.15 Million HKD | 97.0% |
| 2022 Q3 | 119.37 Million HKD | -54.51% |
| 2022 Q2 | 262.41 Million HKD | 96.22% |
| 2021 FY | 482.88 Million HKD | -13.11% |
| 2021 Q1 | 94.32 Million HKD | -52.02% |
| 2021 Q2 | 225.42 Million HKD | 139.0% |
| 2021 Q3 | 133 Million HKD | -41.0% |
| 2021 Q4 | 252.1 Million HKD | 89.55% |
| 2020 FY | 555.74 Million HKD | -25.77% |
| 2020 Q1 | 121.63 Million HKD | 497.19% |
| 2020 Q2 | 359.15 Million HKD | 195.28% |
| 2020 Q4 | 196.59 Million HKD | 0.0% |
| 2019 Q2 | 330.55 Million HKD | 100.0% |
| 2019 Q3 | -33.66 Million HKD | -110.18% |
| 2019 Q1 | 165.27 Million HKD | 14.2% |
| 2019 FY | 748.7 Million HKD | 32.99% |
| 2019 Q4 | 20.36 Million HKD | 160.5% |
| 2018 Q2 | 136.77 Million HKD | 0.0% |
| 2018 Q4 | 144.72 Million HKD | 0.0% |
| 2018 FY | 562.99 Million HKD | 67.12% |
| 2018 Q1 | 136.77 Million HKD | 35.34% |
| 2018 Q3 | 144.72 Million HKD | 5.81% |
| 2017 Q1 | 67.37 Million HKD | 49.65% |
| 2017 FY | 336.87 Million HKD | 257.92% |
| 2017 Q4 | 101.05 Million HKD | 0.0% |
| 2017 Q3 | 101.05 Million HKD | 49.99% |
| 2017 Q2 | 67.37 Million HKD | 0.0% |
| 2016 Q2 | 2.03 Million HKD | 0.0% |
| 2016 Q4 | 45.02 Million HKD | 0.0% |
| 2016 Q3 | 45.02 Million HKD | 2110.8% |
| 2016 Q1 | 2.03 Million HKD | 5.27% |
| 2016 FY | 94.11 Million HKD | 288.89% |
| 2015 Q2 | 10.16 Million HKD | 0.0% |
| 2015 Q3 | 1.93 Million HKD | -80.97% |
| 2015 Q4 | 1.93 Million HKD | 0.0% |
| 2015 FY | 24.2 Million HKD | -65.47% |
| 2015 Q1 | 10.16 Million HKD | -22.99% |
| 2014 Q3 | 13.2 Million HKD | -39.56% |
| 2014 Q4 | 13.2 Million HKD | 0.0% |
| 2014 Q2 | 21.84 Million HKD | 0.0% |
| 2014 Q1 | 21.84 Million HKD | -5.68% |
| 2014 FY | 70.08 Million HKD | -0.67% |
| 2013 Q3 | 23.15 Million HKD | 91.05% |
| 2013 FY | 70.55 Million HKD | 19.93% |
| 2013 Q1 | 12.12 Million HKD | -10.02% |
| 2013 Q2 | 12.12 Million HKD | 0.0% |
| 2013 Q4 | 23.15 Million HKD | 0.0% |
| 2012 FY | 58.83 Million HKD | -47.4% |
| 2012 Q3 | 13.47 Million HKD | -8.41% |
| 2012 Q2 | 14.7 Million HKD | 0.0% |
| 2012 Q4 | 13.47 Million HKD | 0.0% |
| 2012 Q1 | 14.7 Million HKD | 0.0% |
| 2011 Q2 | 27.96 Million HKD | 0.0% |
| 2011 Q4 | 14.7 Million HKD | -47.4% |
| 2011 FY | 111.84 Million HKD | 115.72% |
| 2011 Q1 | 27.96 Million HKD | 0.0% |
| 2011 Q3 | 27.96 Million HKD | 0.0% |
| 2010 Q4 | 27.96 Million HKD | 115.72% |
| 2010 Q1 | 12.96 Million HKD | 0.0% |
| 2010 Q2 | 12.96 Million HKD | 0.0% |
| 2010 FY | 51.84 Million HKD | 0.0% |
| 2010 Q3 | 12.96 Million HKD | 0.0% |
| 2009 Q4 | 12.96 Million HKD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | -181.476% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 92.776% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | -1537.625% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | -19.371% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 1423.742% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | 14.514% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | 69.383% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -117.557% |
| SSY Group Limited | 3.48 Billion HKD | 86.493% |
| JBM (Healthcare) Limited | 319.41 Million HKD | -47.548% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | 24.043% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 98.913% |